| 113.83 Delayed Data As of Nov 16 |  +1.63 / +1.45%Today’s Change | 73.69 Today|||52-Week Range 116.61 | +34.77% Year-to-Date |
| Previous close | 112.20 |
| Today’s open | 111.68 |
| Day’s range | 111.67 - 114.30 |
| Volume | 4,766,426 |
| Average volume (3 months) | 4,175,183 |
| Market cap | $118.9B |
| Earnings growth (last year) | -107.34% |
| Earnings growth (this year) | +29.78% |
| Earnings growth (next 5 years) | +12.60% |
| Revenue growth (last year) | +7.77% |
| P/E ratio | 242.2 |
| Price/Sales | 3.88 |
| Price/Book | 10.65 |
| Today’s change | Today’s % change | |
|---|---|---|
| ABTAbbott Laboratories | +1.31 | +1.85% |
| SNYSanofi | +0.53 | +1.19% |
| ABBVAbbVie | +1.39 | +1.54% |
| AZNAstraZeneca | -0.73 | -1.76% |
| Next reporting date | February 13, 2019 |
| EPS forecast (this quarter) | $1.34 |
| Annual revenue (last year) | $22.9B |
| Annual profit (last year) | -$204.1M |
| Net profit margin | -0.89% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman, President & Chief Executive Officer David A. Ricks |
Senior VP-Biotechnology & Autoimmunity Research Thomas F. Bumol |
Corporate headquarters Indianapolis, Indiana |
